TREM2 Attenuates Aβ1-42-Mediated Neuroinflammation in BV-2 Cells by Downregulating TLR Signaling

  • Huiping Long
  • Gang Zhong
  • Chengzhi Wang
  • Jian Zhang
  • Yueling Zhang
  • Jinglian Luo
  • Shengliang ShiEmail author
Original Paper


The pathogenesis of late-onset Alzheimer's disease (LOAD) mainly involves abnormal accumulation of extracellular β-amyloid (Aβ) and the consequent neurotoxic effects. The triggering receptor expressed on myeloid cells 2 (TREM2) gene is associated with the pathogenesis of LOAD and plays important roles in mediating the phagocytosis of Aβ by microglia and regulating inflammation in central nervous system. However, the exact mechanisms of these processes have not yet been clarified. In this study, we investigated the mechanism by which TREM2 regulates neuroinflammation and promotes Aβ1-42 clearance by BV-2 cells and further elucidated the underlying molecular mechanisms. We either silenced or overexpressed TREM2 in BV-2 cells and evaluated the cell viability, Aβ1-42 content, and expression of inflammatory markers (IL-1β, IL-6, and TNF-α). TREM2 overexpression up-regulated cell activity, promoted clearance of Aβ1-42 by BV-2 cells, and down-regulated expression of the inflammatory factors. In addition, TREM2 overexpression downregulation the expression of the TLR family (TLR2, TLR4 and TLR6) in BV-2 cells. Moreover, LPS, as an agonist of the TLR family, up-regulated the expression of inflammatory cytokines (IL-1β, TNF-α, and IL-6) in BV-2 cells overexpressing TREM2. In conclusion, TREM2 promoted clearance of Aβ1-42 by BV-2 cells and restored BV-2 cell viability from Aβ1-42-mediated neuroinflammation by downregulating TLRs. These findings suggest that TREM2 may be a target for LOAD therapy.


Alzheimer's disease TREM2 TLR signaling Neuroinflammation 



This work was supported by the Natural Science Foundation of China (Grant No. 81460183).

Compliance with Ethical Standards

Conflict of interest

The authors declare that they have no conflict of interest.


  1. 1.
    Rao AT, Degnan AJ, Levy LM (2014) Genetics of Alzheimer disease. AJNR Am J Neuroradiol 35(3):457–458Google Scholar
  2. 2.
    Spires-Jones TL, Hyman BT (2014) The intersection of amyloid beta and tau at synapses in Alzheimer's disease. Neuron 82(4):756–771Google Scholar
  3. 3.
    Kepp KP (2017) Ten challenges of the amyloid hypothesis of Alzheimer's disease. J Alzheimers Dis 55(2):447–457Google Scholar
  4. 4.
    Grupe A et al (2007) Evidence for novel susceptibility genes for late-onset Alzheimer's disease from a genome-wide association study of putative functional variants. Hum Mol Genet 16(8):865–873Google Scholar
  5. 5.
    Roe CM, Grant EA, Hassenstab J (2013) Amyloid imaging and CSF biomarkers in predicting cognitive impairment up to 7.5 years later. Am Acad Neurol 80(19):1784–1791Google Scholar
  6. 6.
    Villemagne VL et al (2013) Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study. Lancet Neurol 12(4):357–367Google Scholar
  7. 7.
    Harry GJ (2013) Microglia during development and aging. Pharmacol Ther 139(3):313–326Google Scholar
  8. 8.
    El Khoury J, Luster AD (2008) Mechanisms of microglia accumulation in Alzheimer's disease: therapeutic implications. Trends Pharmacol Sci 29(12):626–632Google Scholar
  9. 9.
    Perry VH, Teeling J (2013) Microglia and macrophages of the central nervous system: the contribution of microglia priming and systemic inflammation to chronic neurodegeneration. Semin Immunopathol 35(5):601–612Google Scholar
  10. 10.
    Noda M, Suzumura A (2012) Sweepers in the CNS: microglial migration and phagocytosis in the Alzheimer disease pathogenesis. Int J Alzheimers Dis. Google Scholar
  11. 11.
    Zheng H et al (2016) Opposing roles of the triggering receptor expressed on myeloid cells 2 and triggering receptor expressed on myeloid cells-like transcript 2 in microglia activation. Neurobiol Aging 42:132–141Google Scholar
  12. 12.
    Jay TR, von Saucken VE, Landreth GE (2017) TREM2 in neurodegenerative diseases. Mol Neurodegener 12(1):56Google Scholar
  13. 13.
    Mizuno T (2012) The biphasic role of microglia in Alzheimer's disease. Int J Alzheimers Dis. Google Scholar
  14. 14.
    Hickman SE, El Khoury J (2014) TREM2 and the neuroimmunology of Alzheimer's disease. Biochem Pharmacol 88(4):495–498Google Scholar
  15. 15.
    Ito H, Hamerman JA (2012) TREM-2, triggering receptor expressed on myeloid cell-2, negatively regulates TLR responses in dendritic cells. Eur J Immunol 42(1):176–185Google Scholar
  16. 16.
    MagaliTerme ET, Maruyama K, Crépineau F, Chaput N, Flament C, (2014) IL-4 confers NK stimulatory capacity to murine dendritic cells: a signaling pathway involving KARAP/DAP12-triggering receptor expressed on myeloid cell 2 molecules. J Immunol 172(10):5957–5966Google Scholar
  17. 17.
    Jonsson T et al (2013) Variant of TREM2 associated with the risk of Alzheimer's disease. N Engl J Med 368(2):107–116Google Scholar
  18. 18.
    Guerreiro R et al (2013) TREM2 variants in Alzheimer's disease. N Engl J Med 368(2):117–127Google Scholar
  19. 19.
    Fahrenhold M et al (2018) TREM2 expression in the human brain: a marker of monocyte recruitment? Brain Pathol 28(5):595–602Google Scholar
  20. 20.
    Jiang T et al (2014) Triggering receptor expressed on myeloid cells 2 knockdown exacerbates aging-related neuroinflammation and cognitive deficiency in senescence-accelerated mouse prone 8 mice. Neurobiol Aging 35(6):1243–1251Google Scholar
  21. 21.
    Kosack L et al (2017) The lipid-sensor TREM2 aggravates disease in a model of LCMV-induced hepatitis. Sci Rep 7(1):11289Google Scholar
  22. 22.
    Rohn TT (2013) The triggering receptor expressed on myeloid cells 2: "TREM-ming" the inflammatory component associated with Alzheimer's disease. Oxid Med Cell Longev. Google Scholar
  23. 23.
    Wang Y et al (2015) TREM2 lipid sensing sustains the microglial response in an Alzheimer's disease model. Cell 160(6):1061–1071Google Scholar
  24. 24.
    Melchior B et al (2010) Dual induction of TREM2 and tolerance-related transcript, Tmem176b, in amyloid transgenic mice: implications for vaccine-based therapies for Alzheimer's disease. ASN Neuro 2(3):e00037Google Scholar
  25. 25.
    Kawai T, Akira S (2010) The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat Immunol 11(5):373–384Google Scholar
  26. 26.
    Zhang W et al (2012) Increased expressions of TLR2 and TLR4 on peripheral blood mononuclear cells from patients with Alzheimer's disease. J Neurol Sci 315(1–2):67–71Google Scholar
  27. 27.
    Olson JK, Miller SD (2004) Microglia initiate central nervous system innate and adaptive immune responses through multiple TLRs. J Immunol 173(6):3916–3924Google Scholar
  28. 28.
    Seno H et al (2009) Efficient colonic mucosal wound repair requires Trem2 signaling. Proc Natl Acad Sci USA 106(1):256–261Google Scholar
  29. 29.
    Herz J et al (2017) Myeloid cells in the central nervous system. Immunity 46(6):943–956Google Scholar
  30. 30.
    Takahashi K, Rochford CD, Neumann H (2005) Clearance of apoptotic neurons without inflammation by microglial triggering receptor expressed on myeloid cells-2. J Exp Med 201(4):647–657Google Scholar
  31. 31.
    Song M et al (2011) TLR4 mutation reduces microglial activation, increases Aβ deposits and exacerbates cognitive deficits in a mouse model of Alzheimer's disease. J Neuroinflammation 8(1):92Google Scholar
  32. 32.
    Reed-Geaghan EG et al (2009) CD14 and toll-like receptors 2 and 4 are required for fibrillar A{beta}-stimulated microglial activation. J Neurosci 29(38):11982–11992Google Scholar
  33. 33.
    Stewart CR et al (2010) CD36 ligands promote sterile inflammation through assembly of a Toll-like receptor 4 and 6 heterodimer. Nat Immunol 11(2):155–161Google Scholar
  34. 34.
    Tahara K, Kim HD, Jin J-J, Maxwell JA, Li L, Fukuchi K (2006) Role of toll-like receptor signalling in Aβ uptake and clearance. Brain 129(11):3006–3019Google Scholar
  35. 35.
    Town T, Tan J, Sansone N, Obregon D, Klein T, Mullan M (2001) Characterization of murine immunoglobulin G antibodies against human amyloid-β1-42. Neurosci Lett 307(2):101–104Google Scholar
  36. 36.
    Zhao Y et al (2018) TREM2 is a receptor for beta-amyloid that mediates microglial function. Neuron 97(5):1023–1031 (e7)Google Scholar
  37. 37.
    Walker DG, Lue LF (2005) Investigations with cultured human microglia on pathogenic mechanisms of Alzheimer's disease and other neurodegenerative diseases. J Neurosci Res 81(3):412–425Google Scholar
  38. 38.
    Lotz M et al (2005) Amyloid beta peptide 1–40 enhances the action of Toll-like receptor-2 and -4 agonists but antagonizes Toll-like receptor-9-induced inflammation in primary mouse microglial cell cultures. J Neurochem 94(2):289–298Google Scholar
  39. 39.
    Frank S et al (2008) TREM2 is upregulated in amyloid plaque-associated microglia in aged APP23 transgenic mice. Glia 56(13):1438–1447Google Scholar
  40. 40.
    Ford JW, McVicar DW (2009) TREM and TREM-like receptors in inflammation and disease. Curr Opin Immunol 21(1):38–46Google Scholar
  41. 41.
    Aguzzi A, Barres BA, Bennett ML (2013) Microglia: scapegoat, saboteur, or something else? Science 339(116):156–161Google Scholar
  42. 42.
    Zhang Q et al (2018) Anti-inflammatory action of ambuic acid, a natural product isolated from the solid culture of Pestalotiopsis neglecta, through blocking ERK/JNK mitogen-activated protein kinase signaling pathway. Exp Ther Med 16(2):1538–1546Google Scholar
  43. 43.
    Ishizuka EK et al (2016) PAFR activation of NF-kappaB p65 or p105 precursor dictates pro- and anti-inflammatory responses during TLR activation in murine macrophages. Sci Rep 6:32092Google Scholar
  44. 44.
    Cheng Q et al (2018) TREM2-activating antibodies abrogate the negative pleiotropic effects of the Alzheimer's disease variant Trem 2(R47H) on murine myeloid cell function. J Biol Chem 293(32):12620–12633Google Scholar
  45. 45.
    Jiang Y et al (2018) Upregulation of TREM2 ameliorates neuroinflammatory responses and improves cognitive deficits triggered by surgical trauma in Appswe/PS1dE9 mice. Cell Physiol Biochem 46(4):1398–1411Google Scholar
  46. 46.
    Hu N et al (2014) Increased expression of TREM2 in peripheral blood of Alzheimer's disease patients. J Alzheimers Dis 38(3):497–501Google Scholar
  47. 47.
    Rocchio F et al (2019) Gene expression, proteome and calcium signaling alterations in immortalized hippocampal astrocytes from an Alzheimer's disease mouse model. Cell Death Dis 10(1):24Google Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019
corrected publication 2019

Authors and Affiliations

  • Huiping Long
    • 1
  • Gang Zhong
    • 2
  • Chengzhi Wang
    • 3
  • Jian Zhang
    • 1
  • Yueling Zhang
    • 1
  • Jinglian Luo
    • 1
  • Shengliang Shi
    • 1
    Email author
  1. 1.Department of NeurologyThe Second Affiliated Hospital of Guangxi Medical UniversityNanningChina
  2. 2.Guangxi Medical UniversityNanningChina
  3. 3.Department of NeurologyThe Third Affiliated Hospital of Guangxi Medical UniversityNanningChina

Personalised recommendations